# **Data Changes for the CCDD SEPTEMBER Release Candidate 2024**

## **Based on the QA Release Generation 2024-10-01**

|  |  |
| --- | --- |
| **Data entered by** | **A.Raghuveer** |
| **Data checked by** | **M.Taylor** |

## **TM File**

### **Deprecation**

**The following TM concept(s) needs to be added back into the TM File with a status of deprecated. [Reason for deprecation].**

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | **[NONE]** |  |

### **Code permanence – name changes**

**The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].**

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | **[NONE]** |  |

### **Concept permanence - returns**

**The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.**

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8001673 | nilutamide |

## **NTP File**

### **Deprecation**

**The following NTP concept(s) needs to be added back into the NTP File with status of deprecated.**

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | **[NONE]** |  |  |

### **Status update – Inactive**

**The following NTP concept(s) are generating as Active but need to be set to inactive to align with their respective MPs.**

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | **[NONE]** |  | **Inactive** |

### **Code permanence – name changes**

**The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.**

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | **[NONE]** |  |

### **Concept permanence – returns check**

**The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.**

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9005019 | darunavir 150 mg oral tablet |
| 9003139 | nilutamide 50 mg oral tablet |
| 9013486 | oxytocin 10 unit per 1 mL solution for injection ampoule |
| 9013489 | oxytocin 50 unit per 5 mL solution for injection ampoule |

## **MP File**

### **Deprecation (very rare)**

**No new deprecated concepts.**

### **Deprecation – manual return**

**The following MP concepts need to be added back into the MP File with status of deprecated. The product has been transferred from DPD to LNHPD.**

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | **[NONE]** |  | **Deprec** |

### **Status update – deprecation**

**The following MP concepts are generating as active but need to be set to deprecated. Some of these products have been assigned a new DIN, others have been discontinued.**

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | **[NONE]** | **Deprec** |

### **Status update – Inactive**

**The following MP concepts are generating as active but need to be set to inactivated. The DIN is still active but these particular presentations have been discontinued.**

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | **[NONE]** | **Inactive** |

### **DPD descriptors**

**The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **drug\_**  **code** | **mp\_code** | **mp\_formal\_name** | **DPD descriptor** | **DPD descriptor - FR** |
|  |  | **[NONE]** |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **mp\_fr\_description** | **CCDD status** |
|  | **[NONE]** |  |  |  |

### **Code permanence – name changes**

**The following MP concept(s) need to keep its/their existing mp\_code even though their formal name has changed. [Reason for name change].**

|  |  |  |
| --- | --- | --- |
| **mp\_code (to keep)** | **mp \_formal\_name** | **mp\_code in QA Release was** |
|  | **[NONE]** |  |

### **Concept permanence – returns check**

**The following MPs need to be added to the Inclusion list to make sure that they (and their associated NTPs/TMs) continue to be present in the release:**

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 43312 | 2221861 | ANANDRON (nilutamide 50 mg oral tablet) CHEPLAPHARM ARZNEIMITTEL GMBH | Dormant 2024.08.03 |
| 76584 | 2280167 | ASATAB 80 MG CHEWABLE TABLETS (acetylsalicylic acid 80 mg chewable tablet) ODAN LABORATORIES LTD | Dormant 2024.08.11 |
| 75311 | 2267691 | MEDI-WHITE PETROLATUM OINTMENT (white petrolatum 100 % cutaneous ointment) MEDISCA PHARMACEUTIQUE INC | Cancelled post-market Expiry 2024.09.30 |
| NA | 77700912 | OXYTOCIN INJECTION USP (oxytocin 10 unit per 1 mL solution for injection ampoule) PFIZER CANADA ULC | Dormant 2024.09.25 |
| NA | 77700913 | OXYTOCIN INJECTION USP (oxytocin 50 unit per 5 mL solution for injection ampoule) PFIZER CANADA ULC | Dormant 2024.09.25 |
| 85467 | 2369753 | PREZISTA (darunavir (darunavir ethanolate) 150 mg oral tablet) JANSSEN INC | Cancelled post-market Expiry 2024.09.30 |
| 74816 | 2262800 | STRATTERA (atomoxetine (atomoxetine hydrochloride) 10 mg oral capsule) ELI LILLY CANADA INC | Cancelled post-market Expiry 2024.09.16 |
| NA | 77700982 | TARO-OXALIPLATIN (oxaliplatin 100 mg per 20 mL solution for injection vial) TARO PHARMACEUTICALS INC | Cancelled post-market Expiry 2017.10.31 |
| NA | 77700983 | TARO-OXALIPLATIN (oxaliplatin 200 mg per 40 mL solution for injection vial) TARO PHARMACEUTICALS INC | Cancelled post-market Expiry 2017.10.31 |
| NA | 77700984 | TARO-OXALIPLATIN (oxaliplatin 50 mg per 10 mL solution for injection vial) TARO PHARMACEUTICALS INC | Cancelled post-market Expiry 2017.10.31 |
| 73019 | 2248657 | VISINE FOR RED EYE TRIPLE ACTION (dextran 70 0.1 % and polyethylene glycol 400 1 % and povidone 1 % and tetrahydrozoline hydrochloride 0.05 % ophthalmic drops) JOHNSON & JOHNSON INC | Cancelled post-market Expiry 2024.09.30 |
| 92041 | 2436086 | VISINE FOR RED EYE WORKPLACE (dextran 70 0.1 % and polyethylene glycol 400 1 % and povidone 1 % and tetrahydrozoline hydrochloride 0.05 % ophthalmic drops) JOHNSON & JOHNSON INC | Cancelled post-market Expiry 2024.09.30 |
| 61874 | 2238454 | XELODA (capecitabine 500 mg oral tablet) CHEPLAPHARM ARZNEIMITTEL GMBH | Cancelled post-market Expiry 2024.09.30 |

## **Exclusion List (on GitHub)**

**The following changes have been made to the Exclusion List for the OCT 2024 Release Candidate. The list as it is on GitHub should be used.**

**Changes that have been made to the Exclusion List are as follows:  
ACTION is either:**

* **STAY on Exclusion List**
* **ADD to Exclusion List**
* **REMOVE from Exclusion List**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 02515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |
| bb936839bada78f721f72cfd99081f0c | methylphenidate hydrochloride 5 mg per mL NA | 103027 | 2541637 | QUILLIVANT ER ORAL SUSPENSION (methylphenidate hydrochloride 5 mg per mL NA) KYE PHARMACEUTICALS INC. | REMOVE |
| 68828ecaf415824f635c90a9874551ec | inebilizumab 10 mg per mL solution for injection | 103800 | 2549123 | EBGLYSS (lebrikizumab 250 mg per 2 mL solution for injection) ELI LILLY CANADA INC | ADD |
| 3b1049efd181b7d24799389eb57b9729 | ondansetron 4 mg per 5 mL oral solution | 101313 | 2524090 | MINT-ONDANSETRON SOLUTION (ondansetron 4 mg per 5 mL oral solution) MINT PHARMACEUTICALS INC | ADD |
| 7f1a3b8d79949556ea625be09688f733 | lebrikizumab 250 mg per 2 mL solution for injection | 103236 | 2543931 | UPLIZNA (inebilizumab 10 mg per mL solution for injection) HORIZON THERAPEUTICS IRELAND DAC | ADD |
|  |  | 89896 | 2414309 | DUAL INTENSIVE ACNE TREATMENT | ADD |
|  |  | 95852 | 2469707 | RODAN+FIELDS SPOTLESS | ADD |